The first Pichia kluyveri strain developed as a probiotic
At the heart of Biohm Technologies’ Ascomya™ fungal probiotic platform is PK88™—the first Pichia kluyveri strain developed as a probiotic. Discovered through Symbiont®, PK88™ has a distinctive profile: beta-glucans in its cell wall, antioxidant systems, and the ability to produce bioactive metabolites.
Beta-glucans visualized in the PK88™ cell wall.
Antioxidant systems
Beta-glucans
Bioactive metabolites
Beyond Bacteria
Why Fungi Matter in the Microbiome
More numerous, smaller cells
Fewer, much larger cells
one microbiome
Fungi are less numerous than bacteria in the gut, but their cells are generally much larger—and the two communities interact closely.
Those relationships can influence how microbes grow and behave, adding a dimension to the microbiome that we’re only beginning to explore. For product developers, that opens up possibilities beyond familiar bacterial strains.
From Data to Discovery
Discovery Guided by Symbiont®Biohm’s proprietary gut microbiome data
Pichia identified in healthy microbial communities
Multiple strains screened for safety and functional potential
PK88™ selected
Whole genome sequencing and extensive characterization
Biohm’s proprietary gut microbiome data highlighted Pichia in healthy microbial communities, prompting a closer look at strains with promising safety and functional profiles. PK88™ emerged from that screening and has since undergone whole genome sequencing and extensive characterization to better understand its potential as a probiotic.
Why PK88™ Stands Out
Biohm’s emerging preclinical data1 reveal a distinctive functional profile for PK88™:
Beta-glucans
Beta-glucans in its cell wall offer prebiotic potential and a new angle on microbiome support
GABA & B Vitamins
PK88™ produces GABA and B vitamins, with potential relevance to mood and the gut‑brain axis
Spermidine & Antioxidants
Spermidine production and antioxidant systems offer avenues to explore cellular health and healthy aging
These findings are driving ongoing human clinical research.
Formulating with PK88™
A Novel Probiotic Yeast for Your Next ProductPK88™ is recommended at 100 million CFU and is suitable for capsules, tablets and powders. As the first ingredient in the Ascomya™ fungal probiotic platform, it offers a differentiated option for brands expanding beyond traditional bacterial probiotics.
CFU
Capsules
Tablets
Powders
Quality Attributes